Hidradenitis Suppurativa Hs clinical trials

Explore recruiting hidradenitis suppurativa hs clinical trials.

Recruiting hidradenitis suppurativa hs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hidradenitis Suppurativa Hs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-302)

Netherlands, Slovakia, Czechia, France, Bulgaria, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult and adolescent patients with moderate to severe hidradenitis suppurativa (RECHARGE-1)

Bulgaria, Poland, Germany, Spain, Italy, Portugal +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Germany, Ireland, Greece, Bulgaria, Spain, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)

Netherlands, Germany, Poland, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

Hungary, Spain, France, Belgium, Sweden, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Hidradenitis Suppurativa Hs trials by city

Hidradenitis Suppurativa Hs in Toronto Hidradenitis Suppurativa Hs in Vancouver Hidradenitis Suppurativa Hs in Montreal Hidradenitis Suppurativa Hs in Calgary Hidradenitis Suppurativa Hs in Edmonton Hidradenitis Suppurativa Hs in Ottawa Hidradenitis Suppurativa Hs in Winnipeg Hidradenitis Suppurativa Hs in Quebec City Hidradenitis Suppurativa Hs in Hamilton Hidradenitis Suppurativa Hs in Kitchener Hidradenitis Suppurativa Hs in London Hidradenitis Suppurativa Hs in Halifax Hidradenitis Suppurativa Hs in New York Hidradenitis Suppurativa Hs in Los Angeles Hidradenitis Suppurativa Hs in Chicago Hidradenitis Suppurativa Hs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease